Enfermedades de la secreción de aldosterona

  1. Ituguerri Guevara, M. 1
  2. Larrán Escandón, L. 1
  3. López Tinoco, C. 2
  1. 1 Servicio de Endocrinología y Nutrición, Hospital Universitario Puerta del Mar, Cádiz, España
  2. 2 Servicio de Endocrinología y Nutrición, Hospital Universitario Puerta del Mar, Cádiz, España Departamento de Medicina, Universidad de Cádiz, Cádiz, España
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2020

Issue Title: Enfermedades endocrinológicas y metabólicas (VII)Patología suprarrenal

Series: 13

Issue: 19

Pages: 1072-1082

Type: Article

DOI: 10.1016/J.MED.2020.10.012 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Hyper- and hypoaldosteronism are caused by an excessive or insufficient adrenal secretion of aldosterone, respectively. Idiopathic bilateral hyperplasia and aldosterone-producing adenoma are the commonest causes of primary hyperaldosteronism. Primary hyperaldosteronism is characterized by hypertension, hypokalemia and metabolic alkalosis; in turn, hypoaldosteronism presents hyperkalemia and metabolic acidosis. The aldosterone/plasma renin activity ratio (ARR) is routinely used as a screening test of primary hyperaldosteronism. Functional tests are recommended if ARR is high (salt-loading, intravenous or oral, and fludrocortisone or captopril suppression). Once diagnostic is confirmed, imaging studies (abdominal computed tomography —CT—) and adrenal vein catheterization (in patients for surgery) have to be performed. Plasma levels of aldosterone and renin activity have to be determined by stimulatory functional tests (response to posture and volume depletion tests). Unilateral laparoscopic adrenalectomy is recommended in primary hyperaldosteronism caused by unilateral hyperplasia or adenoma; mineralocorticoid (spironolactone) receptor antagonists are the first-choice treatment for bilateral cases and in patients considered unfit for surgery. Potassium restriction and mineralocorticoid replacement therapy with fludrocortisone is the treatment of hypoaldosteronism.

Bibliographic References

  • J.W. Funder , R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata, et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline J Clin Endocrinol Metab., 101 (5) (2016), pp. 1889-1916
  • A. Hannemann , H. Wallaschofski Prevalence of primary aldosteronism in patient's cohorts and in population-based studies-- a review of the current literature Horm Metab Res., 44 (3) (2012), pp. 157-162
  • S. Douma , K. Petidis, M. Doumas, P. Papaefthimiou, A. Triantafyllou, N. Kartali, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study Lancet., 371 (9628) (2008), pp. 1921-1926
  • P. Mulatero , D. Tizzani, A. Viola, C. Bertello, S. Monticone, G. Mengozzi, et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms) Hypertension., 58 (5) (2011), pp. 797-803
  • R.P. Lifton , R.G. Dluhy, M. Powers, G.M. Rich, M. Gutkin, F. Fallo, et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase Nature Genetics., 2 (1) (1992), pp. 66-74
  • W.R. Litchfield , C. Coolidge, P. Silva, R.P. Lifton, F. Fallo, G.H. Williams, et al. Impaired potassium-stimulated aldosterone production: a possible explanation for normokalemic glucocorticoid-remediable aldosteronism J Clin Endocrinol Metab., 82 (5) (1997), pp. 1507-1510
  • A. Pallauf , C. Schirpenbach, O. Zwermann, E. Fischer, M. Morak, E. Holinski-Feder, et al. The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience Horm Metab Res., 44 (3) (2012), pp. 215-220
  • M. Choi , U.I. Scholl, P. Yue, P. Bjorklund, B. Zhao, C. Nelson-Williams, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension Science., 331 (6018) (2011), pp. 768-772
  • G. Daniil , F.L. Fernandes-Rosa, J. Chemin, I. Blesneac, J. Beltrand, M. Polak, et al. CACNA1H mutations are associated with different forms of primary aldosteronism EBioMedicine., 13 (2016), pp. 225-236
  • P. Milliez , X. Girerd, P.-F. Plouin, J. Blacher, M.E. Safar, J.-J. Mourad Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J Am Coll Cardiol., 45 (8) (2005), pp. 1243-1248
  • M. Stowasser , J. Sharman, R. Leano, R.D. Gordon, G. Ward, D. Cowley, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I J Clin Endocrinol Metab., 90 (9) (2005), pp. 5070-5076
  • A. Markou , T. Pappa, G. Kaltsas, A. Gouli, K. Mitsakis, P. Tsounas, et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension J Clin Endocrinol Metab., 98 (4) (2013), pp. 1409-1416
  • P. Mulatero , M. Stowasser, K.-C. Loh, C.E. Fardella, R.D. Gordon, L. Mosso, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents J Clin Endocrinol Metab., 89 (3) (2004), pp. 1045-1050
  • G.P. Rossi , G. Bernini, C. Caliumi, G. Desideri, B. Fabris, C. Ferri, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients J Am Coll Cardiol., 48 (11) (2006), pp. 2293-2300
  • S. Monticone , F. D’Ascenzo, C. Moretti, T.A. Williams, F. Veglio, F. Gaita , et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis Lancet Diabetes Endocrinol., 6 (1) (2018), pp. 41-50
  • G. Hanslik , H. Wallaschofski, A. Dietz, A. Riester, M. Reincke, B. Allolio, et al. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry Eur J Endocrinol., 173 (5) (2015), pp. 665-675
  • W. Arlt , K. Lang, A.J. Sitch, A.S. Dietz, Y. Rhayem, I. Bancos, et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism JCI Insight., 2 (8) (2017), p. e93136
  • W.F. Young Diagnosis and treatment of primary aldosteronism: practical clinical perspectives J Intern Med., 285 (2) (2019), pp. 126-148
  • W.F. Young Primary aldosteronism: renaissance of a syndrome Clin Endocrinol., 66 (5) (2007), pp. 607-618
  • L. Mosso , C. Carvajal, A. González, A. Barraza, F. Ávila, J. Montero, et al. Primary aldosteronism and hypertensive disease Hypertension., 42 (2) (2003), pp. 161-165
  • T.A. Williams , M. Reincke Management of endocrine disease: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited Eur J Endocrinol., 179 (1) (2018), pp. R19-R29
  • J. Morera , Y. Reznik Management of endocrine disease: The role of confirmatory tests in the diagnosis of primary aldosteronism Eur J Endocrinol., 180 (2) (2019), pp. R45-R58
  • M. Stowasser , A.H. Ahmed, D. Cowley, M. Wolley, Z. Guo, B.C. McWhinney, et al.Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism J Clin Endocrinol Metab., 103 (11) (2018), pp. 4113-4124
  • M.L.V. Lahera Vargas Hiperaldosteronismo primario En: Manual de Endocrinología y Nutrición de la SEEN [Internet] (2015) Disponible en: http://manual.seen.es/home/init
  • P. Mulatero , C. Bertello, C. Garrone, D. Rossato, G. Mengozzi, A. Verhovez, et al. Captopril test can give misleading results in patients with suspect primary aldosteronism Hypertension., 50 (2007), pp. e26-e27
  • C. Hambling , R.T. Jung, A. Gunn, M.C. Browning, W.A. Bartlett Re-evaluation of the captopril test for the diagnosis of primary hyperaldosteronism Clin Endocrinol., 36 (5) (1992), pp. 499-503
  • K. Nanba , T. Tamanaha, K. Nakao, S.-T. Kawashima, T. Usui, T. Tagami, et al. Confirmatory testing in primary aldosteronism J Clin Endocrinol Metab., 97 (5) (2012), pp. 1688-1694
  • T. Nishikawa , M. Omura, F. Satoh, H. Shibata, K. Takahashi, N. Tamura, et al. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009 Endocr J., 58 (9) (2011), pp. 711-721
  • V. Lim , Q. Guo, C.S. Grant, G.B. Thompson, M.L. Richards, D.R. Farley, et al. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism J Clin Endocrinol Metab., 99 (8) (2014), pp. 2712-2719
  • M.J.E. Kempers , J.W.M. Lenders, L. van Outheusden, G.J. van der Wilt, L.J. Schultze Kool, A.R.M.M. Hermus, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism Ann Intern Med., 151 (5) (2009), pp. 329-337
  • O. Vonend , N. Ockenfels, X. Gao, B. Allolio, K. Lang, K. Mai, et al. Adrenal venous sampling: evaluation of the German Conn's registry Hypertension., 57 (5) (2011), pp. 990-995
  • A. Harvey , G. Kline, J.L. Pasieka Adrenal venous sampling in primary hyperaldosteronism: comparison of radiographic with biochemical success and the clinical decision-making with “less than ideal” testing Surgery., 140 (6) (2006), pp. 845-847
  • W.F. Young , A.W. Stanson What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol., 70 (1) (2009), pp. 14-17
  • G. Kline , D.T. Holmes Adrenal venous sampling for primary aldosteronism: laboratory medicine best practice J Clin Pathol., 70 (11) (2017), pp. 911-916
  • I. Christakis , J.A. Livesey, G.P. Sadler, R. Mihai Laparoscopic adrenalectomy for Conn's syndrome is beneficial to patients and is cost effective in England J Invest Surg., 31 (4) (2018), pp. 300-306
  • M. Sywak , J.L. Pasieka Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism Br J Surg., 89 (12) (2002), pp. 1587-1593
  • B. Lechner , K. Lechner, D. Heinrich, C. Adolf, F. Holler, H. Schneider, et al. Therapy of endocrine disease: Medical treatment of primary aldosteronism Eur J Endocrinol., 181 (4) (2019), pp. R147-R153
  • C. Wilczynski , L. Shah, M.A. Emanuele, N. Emanuele, A. Mazhari Selective hypoaldosteronism: a review Endocr Practice., 21 (8) (2015), pp. 957-965
  • L.A.P. Vilela , M.Q. Almeida Diagnosis and management of primary aldosteronism Arch Endocrin Metab., 61 (3) (2017), pp. 305-312
  • F.T. Lee , D. Elaraj Evaluation and management of primary hyperaldosteronism Surg Clin N Am., 99 (4) (2019), pp. 731-745
Data source: Dialnet